Division of Osteologix Holdings PLC
Latest From Osteologix AS
The EU's pharmacovigilance committee PRAC has recommended to the CHMP that the marketing authorization for Servier's osteoporosis drug Protelos/Osseor (strontium ranelate) be suspended. The product's fate now awaits the CHMP's next meeting on 20-23 January.
AmpliPhi Biosciences, a developer of bacteriophage-based antibacterial therapies, has appointed Philip Young president and CEO. Mr Young was formerly president and CEO of Osteologix, and is still on its board of directors. Edward Cappabianca, AmpliPhi's last CEO, has left the company and the board of directors to pursue other interests.
Osteologix, a US speciality pharma company focused on diseases of the bone and joints, has granted Servier Research Group of France an exclusive royalty-bearing licence to its lead product candidate, NB S101 (strontium malonate).
Each month, Start-Up presents a comprehensive review of young, private life science companies that have recieved venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Osteologix Inc.
- Western Europe
- Parent & Subsidiaries
- Osteologix Holdings PLC
- Senior Management
Philip J Young, CEO
Baxter Phillips, III, Senior. Dir., Corporate Dev.
- Contact Info
Phone: (45) 39179730
Symbion Science Park